Probiotic capsules made a modest dent in acne, but the evidence is thin

Acne vulgaris is one of the most common chronic inflammatory skin conditions in adolescents and young adults worldwide, and the standard playbook leans heavily on antibiotics. Growing concern about antimicrobial resistance has pushed researchers to look for treatments that spare antibiotics altogether. One candidate is the microbiome itself: if gut microbes influence skin inflammation, then oral probiotics might shift acne severity from the inside. This review set out to test whether the trial evidence for that idea actually holds up.

The authors ran a systematic review and meta-analysis following PRISMA 2020 guidelines, searching PubMed, Embase, Web of Science and ClinicalTrials.gov through November 2025 with no language restrictions. They only accepted double-blind randomised controlled trials that compared oral probiotics against placebo or standard therapy for at least 4 weeks and reported quantitative acne severity outcomes. Three trials totalling 231 participants met the bar. Risk of bias was assessed with a standard tool, results were pooled with modern random-effects methods, and adverse events were extracted from each trial.

Pooled analysis suggested a modest reduction in inflammatory lesion counts favouring probiotics, with a standardised mean difference of -0.57. The catch is that the trials disagreed with each other substantially, and the 95% prediction interval ran from -1.25 to 0.11, meaning a future study could plausibly find no meaningful effect. Sensitivity analyses using an alternative statistical approach produced comparable results. All three trials reported good short-term tolerability with no serious adverse events. Risk of bias was low in two trials and of some concern in one, and the certainty of evidence was rated low to moderate.

This is one of the more rigorous looks at oral probiotics for acne, restricted to double-blind randomised trials rather than the looser designs that often pad out this literature. It supports the idea of probiotics as a generally safe, antibiotic-sparing adjunct, but it also exposes how little solid evidence exists: three trials is a very narrow base, and the inconsistency between them leaves the true size of any effect uncertain. The authors call for larger, standardised trials before any firm clinical recommendation can be made.

If you deal with acne and dislike the idea of long antibiotic courses, this is a reason to keep an eye on probiotic research rather than a reason to expect results from a capsule today. The pooled signal points the right way and safety looked good in the short term, but the evidence is small, the trials disagreed, and future studies may find nothing meaningful. Anyone weighing acne treatment options still has far stronger evidence behind the established approaches, and this finding does not change that picture yet.